{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:24:12Z","timestamp":1780086252602,"version":"3.54.0"},"reference-count":62,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Measurement of patient-reported outcomes (PROs) and health-related quality of life (HrQOL) are crucial for comprehensive, patient-centered cancer care. Both PROs and HrQOL have been understudied in patients with Erdheim-Chester disease (ECD), a rare cancer with protean manifestations, dense symptomatology, and frequent diagnostic delay. We sought to evaluate the longitudinal evolution of symptom burden and unmet supportive care needs in patients with ECD, and to identify associations between these PROs and HrQOL. A registry-based cohort of patients with ECD completed a PRO battery including the Functional Assessment of Cancer Therapy-General (FACT-G) and other validated PRO measures. Descriptive statistics were used to characterize the distribution of PROs and FACT-G scores; PROs were modeled by univariable linear regression with FACT-G total score as the dependent variable at (1) registry enrollment and (2) 12-month time points. Changes in FACT-G total score (the difference between the 12-month and enrollment scores) were correlated with changes in PROs using univariable linear regression analysis. In 158 patients, mean total FACT-G was 70.8, lower than observed across multiple cancer cohorts. Higher levels of pain and fatigue, presence of neurologic symptoms, and greater number of unmet needs were all associated with worse HrQOL. Improvement in pain, fatigue, and unmet needs over 12 months was significantly associated with improvement in HrQOL. In patients with ECD, HrQOL is substantially diminished, even when considering other patients with cancer. Mitigation of symptoms and addressing unmet supportive care needs represent opportunities for intervention to improve HrQOL in ECD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015659","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T16:06:06Z","timestamp":1751472366000},"page":"4415-4424","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Symptoms, unmet needs, and quality of life in Erdheim-Chester disease: a longitudinal registry-based analysis"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8768-7754","authenticated-orcid":false,"given":"Priya H.","family":"Marathe","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1258-6112","authenticated-orcid":false,"given":"Anne S.","family":"Reiner","sequence":"additional","affiliation":[{"name":"2Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Bossert","sequence":"additional","affiliation":[{"name":"3Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Sigler","sequence":"additional","affiliation":[{"name":"3Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Fournier","sequence":"additional","affiliation":[{"name":"4Histiocytosis Association, Pitman, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Brewer","sequence":"additional","affiliation":[{"name":"5Erdheim-Chester Disease Global Alliance, DeRidder, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5177","authenticated-orcid":false,"given":"Gaurav","family":"Goyal","sequence":"additional","affiliation":[{"name":"6Division of Hematology-Oncology, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Atkinson","sequence":"additional","affiliation":[{"name":"7Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-0380","authenticated-orcid":false,"given":"Jun J.","family":"Mao","sequence":"additional","affiliation":[{"name":"8Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine S.","family":"Panageas","sequence":"additional","affiliation":[{"name":"2Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5456-5961","authenticated-orcid":false,"given":"Eli L.","family":"Diamond","sequence":"additional","affiliation":[{"name":"3Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"9Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"2025090909313366500_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","author":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"2025090909313366500_bib2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.6004\/jnccn.2021.0053","article-title":"Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Go","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"16","key":"2025090909313366500_bib3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/blood.2019002766","article-title":"Erdheim-Chester disease","volume":"135","author":"Haroche","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2025090909313366500_bib4","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","article-title":"Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation","volume":"121","author":"Haroche","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2025090909313366500_bib5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.revmed.2014.04.007","article-title":"Erdheim-Chester disease [in French]","volume":"35","author":"Haroche","year":"2014","journal-title":"Rev Med Interne"},{"issue":"2","key":"2025090909313366500_bib6","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1212\/NXI.0000000000000078","article-title":"Complete remission of critical neurohistiocytosis by vemurafenib","volume":"2","author":"Euskirchen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"2025090909313366500_bib7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3109\/0284186X.2015.1120885","article-title":"Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: towards the paradigm of combined targeting and immune therapies","volume":"55","author":"Franconieri","year":"2016","journal-title":"Acta Oncol"},{"key":"2025090909313366500_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13104-015-1135-7","article-title":"Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report","volume":"8","author":"Tzoulis","year":"2015","journal-title":"BMC Res Notes"},{"issue":"10","key":"2025090909313366500_bib9","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00256-016-2431-6","article-title":"Erdheim Chester disease with appendicular skeletal, renal and pleural involvement responding to Zelboraf (BRAF inhibitor) treatment: case report","volume":"45","author":"Borys","year":"2016","journal-title":"Skeletal Radiol"},{"issue":"6","key":"2025090909313366500_bib10","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1097\/IOP.0000000000000866","article-title":"Vemurafenib (BRAF inhibitor) therapy for orbital Erdheim-Chester disease","volume":"33","author":"Gupta","year":"2017","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2025090909313366500_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/OTT.S121615","article-title":"Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim-Chester disease","volume":"10","author":"V\u00e1radi","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"15_suppl","key":"2025090909313366500_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.11012","article-title":"Detection of BRAF mutations in urine and plasma cell-free DNA: application to the diagnosis and management of histiocytic disorder patients [abstract]","volume":"32","author":"Abdel-Wahab","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025090909313366500_bib13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2016-09-740217","article-title":"Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations","volume":"129","author":"Nordmann","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2025090909313366500_bib14","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/NXI.0000000000000299","article-title":"Targeted treatment of brainstem neurohistiocytosis guided by urinary cell-free DNA","volume":"4","author":"Hunt","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"2025090909313366500_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/pde.14887","article-title":"Progressive nodular histiocytosis in a 9-year-old boy treated with cobimetinib","volume":"39","author":"Bujan","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"2025090909313366500_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjh.14284","article-title":"Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease","volume":"180","author":"Cohen Aubart","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"2025090909313366500_bib17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","article-title":"Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)","volume":"130","author":"Cohen Aubart","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2025090909313366500_bib18","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1182\/bloodadvances.2022009013","article-title":"Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis","volume":"7","author":"Aaroe","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2025090909313366500_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"issue":"22","key":"2025090909313366500_bib20","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2019003507","article-title":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era","volume":"135","author":"Goyal","year":"2020","journal-title":"Blood"},{"issue":"14","key":"2025090909313366500_bib21","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","article-title":"What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials","volume":"32","author":"Kotronoulas","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025090909313366500_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","article-title":"Patient reported outcome measures in rare diseases: a narrative review","volume":"13","author":"Slade","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2025090909313366500_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1758834010395342","article-title":"Health-related quality of life and cancer clinical trials","volume":"3","author":"Osoba","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"2025090909313366500_bib24","doi-asserted-by":"crossref","first-page":"dju129","DOI":"10.1093\/jnci\/dju129","article-title":"Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials","volume":"106","author":"Reeve","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"32","key":"2025090909313366500_bib25","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1200\/JCO.2007.12.6672","article-title":"Health-related quality of life and symptom management research sponsored by the National Cancer Institute","volume":"25","author":"Minasian","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025090909313366500_bib26","author":"U.S. Food and Drug Administration","year":"2024"},{"issue":"6","key":"2025090909313366500_bib27","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3324\/haematol.2022.282287","article-title":"Patient-reported fatigue and pain in Erdheim-Chester disease: a registry-based, mixed methods study","volume":"108","author":"Reiner","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"2025090909313366500_bib28","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/bloodadvances.2018030502","article-title":"A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease","volume":"3","author":"Diamond","year":"2019","journal-title":"Blood Adv"},{"key":"2025090909313366500_bib29","doi-asserted-by":"crossref","first-page":"101670","DOI":"10.1016\/j.eclinm.2022.101670","article-title":"Challenges and positive impact of rare cancer caregiving: a mixed-methods study of caregivers of patients with Erdheim-Chester disease and other histiocytic neoplasms","volume":"54","author":"Mitchell","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"19","key":"2025090909313366500_bib30","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1182\/bloodadvances.2023010827","article-title":"Dyadic communication in rare cancer: a registry-based study of patients with Erdheim-Chester disease and their caregivers","volume":"7","author":"Reiner","year":"2023","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2025090909313366500_bib31","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"2025090909313366500_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2025090909313366500_bib33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0163278705275341","article-title":"General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G)","volume":"28","author":"Brucker","year":"2005","journal-title":"Eval Health Prof"},{"issue":"2","key":"2025090909313366500_bib34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0163278705275340","article-title":"Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience","volume":"28","author":"Yost","year":"2005","journal-title":"Eval Health Prof"},{"issue":"2","key":"2025090909313366500_bib35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/0973-1075.84531","article-title":"Utilization of brief pain inventory as an assessment tool for pain in patients with cancer: a focused review","volume":"17","author":"Kumar","year":"2011","journal-title":"Indian J Palliat Care"},{"issue":"8","key":"2025090909313366500_bib36","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.apmr.2014.03.026","article-title":"Psychometric properties of the Brief Fatigue Inventory in community-dwelling older adults","volume":"95","author":"Shuman-Paretsky","year":"2014","journal-title":"Arch Phys Med Rehabil"},{"issue":"4","key":"2025090909313366500_bib37","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1365-2753.2008.01057.x","article-title":"Brief assessment of adult cancer patients' perceived needs: development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34)","volume":"15","author":"Boyes","year":"2009","journal-title":"J Eval Clin Pract"},{"issue":"3 Suppl","key":"2025090909313366500_bib38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S","article-title":"Research in cancer pain. What we know and what we need to know","volume":"67","author":"Cleeland","year":"1991","journal-title":"Cancer"},{"issue":"9","key":"2025090909313366500_bib39","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R","article-title":"The prevalence and severity of pain in cancer","volume":"50","author":"Daut","year":"1982","journal-title":"Cancer"},{"issue":"2","key":"2025090909313366500_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","article-title":"Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases","volume":"17","author":"Daut","year":"1983","journal-title":"Pain"},{"key":"2025090909313366500_bib41","unstructured":"U.S. Department of Health and Human Services\n          . Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. Accessed 5 January 2018. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf."},{"issue":"3","key":"2025090909313366500_bib42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1526-4637.2009.00774.x","article-title":"The Brief Pain Inventory and its \"pain at its worst in the last 24 hours\" item: clinical trial endpoint considerations","volume":"11","author":"Atkinson","year":"2010","journal-title":"Pain Med"},{"key":"2025090909313366500_bib43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2018.06.009","article-title":"Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors","volume":"101","author":"Mao","year":"2018","journal-title":"Eur J Cancer"},{"issue":"10","key":"2025090909313366500_bib44","first-page":"3423","article-title":"The association between fatigue and pain symptoms and decreased physical activity after cancer","volume":"26","author":"Romero","year":"2018","journal-title":"Support Care Cancer"},{"key":"2025090909313366500_bib45","author":"SAS Institute Inc","year":"2023"},{"issue":"1","key":"2025090909313366500_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2017.05.008","article-title":"Quality of life among long-term survivors of advanced stage ovarian cancer: a cross-sectional approach","volume":"146","author":"Lutgendorf","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2025090909313366500_bib47","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hon.2522","article-title":"Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma","volume":"36","author":"Thompson","year":"2018","journal-title":"Hematol Oncol"},{"issue":"8","key":"2025090909313366500_bib48","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.bbmt.2020.04.020","article-title":"Quality of life following allogeneic stem cell transplantation for patients age &gt;60 years with acute myelogenous leukemia","volume":"26","author":"Wright","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2025090909313366500_bib49","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1186\/s12885-024-12612-z","article-title":"Symptom impact and health-related quality of life (HRQoL) assessment by cancer stage: a narrative literature review","volume":"24","author":"Chung","year":"2024","journal-title":"BMC cancer"},{"issue":"Suppl 1","key":"2025090909313366500_bib50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.12-S1-4","article-title":"Cancer-related fatigue: the scale of the problem","volume":"12","author":"Hofman","year":"2007","journal-title":"Oncologist"},{"issue":"12","key":"2025090909313366500_bib51","doi-asserted-by":"crossref","first-page":"758","DOI":"10.6061\/clinics\/2017(12)07","article-title":"Pain and quality of life in breast cancer patients","volume":"72","author":"Costa","year":"2017","journal-title":"Clinics (Sao Paulo)"},{"issue":"8","key":"2025090909313366500_bib52","first-page":"3095","article-title":"Assessing cancer pain-the first step toward improving patients' quality of life","volume":"27","author":"Minello","year":"2019","journal-title":"Support Care Cancer"},{"issue":"3","key":"2025090909313366500_bib53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11136-023-03537-4","article-title":"Associations of frailty with symptoms, and HRQOL in older cancer survivors after cancer treatments: a systematic review and meta-analyses","volume":"33","author":"Han","year":"2024","journal-title":"Qual Life Res"},{"key":"2025090909313366500_bib54","doi-asserted-by":"crossref","first-page":"100047","DOI":"10.1016\/j.oor.2023.100047","article-title":"Changes in supportive care needs over time from diagnosis up to two years after treatment in head and neck cancer patients: a prospective cohort study","volume":"6","author":"Molenaar","year":"2023","journal-title":"Oral Oncol Rep"},{"key":"2025090909313366500_bib55","doi-asserted-by":"crossref","first-page":"1437888","DOI":"10.3389\/fonc.2024.1437888","article-title":"Supportive care needs, quality of life and social support among elderly colorectal cancer patients undergoing chemotherapy: a longitudinal study","volume":"14","author":"Lian","year":"2024","journal-title":"Front Oncol"},{"issue":"11","key":"2025090909313366500_bib56","first-page":"3447","article-title":"The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers","volume":"25","author":"Oberoi","year":"2017","journal-title":"Support Care Cancer"},{"issue":"6","key":"2025090909313366500_bib57","first-page":"e13502","article-title":"Unmet supportive care needs of patients with rare cancer: a systematic review","volume":"30","author":"de Heus","year":"2021","journal-title":"Eur J Cancer Care"},{"issue":"1","key":"2025090909313366500_bib58","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1210\/jc.2015-3357","article-title":"Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim-Chester disease","volume":"101","author":"Courtillot","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090909313366500_bib59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/B978-0-12-820683-6.00010-5","article-title":"Neuroendocrine manifestations of Erdheim-Chester disease","volume":"181","author":"Manaka","year":"2021","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"2025090909313366500_bib60","first-page":"e13525","article-title":"Unmet supportive care needs associated with quality of life for people with lung cancer: a systematic review of the evidence 2007-2020","volume":"31","author":"Cochrane","year":"2022","journal-title":"Eur J Cancer Care"},{"issue":"1","key":"2025090909313366500_bib61","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1186\/s12885-023-11098-5","article-title":"Factors associated with health-related quality of life in a cohort of cancer survivors in New Jersey","volume":"23","author":"Manne","year":"2023","journal-title":"BMC cancer"},{"issue":"5","key":"2025090909313366500_bib62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ejh.12941","article-title":"Distress and unmet needs during treatment and quality of life in early cancer survivorship: a longitudinal study of haematological cancer patients","volume":"99","author":"Oberoi","year":"2017","journal-title":"Eur J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/17\/4415\/2409114\/blooda_adv-2024-015659-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/17\/4415\/2409114\/blooda_adv-2024-015659-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:31:48Z","timestamp":1757424708000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/17\/4415\/546037\/Symptoms-unmet-needs-and-quality-of-life-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":62,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015659","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,9]]},"published":{"date-parts":[[2025,8,28]]}}}